A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs AZD 5363 (Primary)
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Male breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 24 Oct 2017 Results (n=90) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 31 Aug 2017 Planned End Date changed from 28 Dec 2018 to 15 Nov 2019.
- 31 Aug 2017 Planned primary completion date changed from 31 May 2018 to 18 Apr 2019.